--- title: "Perrigo | 10-K: FY2025 Revenue Beats Estimate at USD 4.253 B" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277084005.md" datetime: "2026-02-26T18:38:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277084005.md) - [en](https://longbridge.com/en/news/277084005.md) - [zh-HK](https://longbridge.com/zh-HK/news/277084005.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277084005.md) | [English](https://longbridge.com/en/news/277084005.md) # Perrigo | 10-K: FY2025 Revenue Beats Estimate at USD 4.253 B Revenue: As of FY2025, the actual value is USD 4.253 B, beating the estimate of USD 4.24 B. EPS: As of FY2025, the actual value is USD -10.29. EBIT: As of FY2025, the actual value is USD -1.135 B. #### Consolidated Financial Results - **Gross Profit**: Perrigo Company plc (培瑞克) reported a gross profit of $1,494.5 million in 2025, down from $1,542.7 million in 2024. - **Gross Profit %**: The gross profit percentage was 35.1% in 2025, a decrease of 20 basis points from 35.3% in 2024. - **Operating Income (Loss)**: The company reported an operating loss of -$1,122.2 million in 2025, a significant decrease from an operating income of $112.9 million in 2024. - **Operating Income %**: The operating income percentage was -26.4% in 2025, compared to 2.6% in 2024. - **Net Income (Loss)**: Perrigo Company plc (培瑞克) reported a net loss of -$1,425.4 million in 2025, compared to a net loss of -$171.8 million in 2024. #### Consumer Self-Care Americas (CSCA) Segment - **Net Sales**: CSCA net sales decreased by $108.4 million, or 4.0%, to $2,585.3 million in 2025 from $2,693.7 million in 2024. - **Net Sales by Product Category (2025 vs. 2024)**: - **Upper Respiratory**: $529.5 million (5.8% increase) vs. $500.3 million. - **Digestive Health**: $442.1 million (-11.1% decrease) vs. $497.4 million. - **Nutrition**: $408.5 million (-9.1% decrease) vs. $449.5 million. - **Pain and Sleep-Aids**: $332.5 million (-3.7% decrease) vs. $345.5 million. - **Healthy Lifestyle**: $316.4 million (3.1% increase) vs. $306.8 million. - **Oral Care**: $256.9 million (-6.7% decrease) vs. $275.4 million. - **Skin Care**: $214.9 million (-2.4% decrease) vs. $220.1 million. - **Women’s Health**: $72.4 million (-10.7% decrease) vs. $81.1 million. - **Vitamins, Minerals, and Supplements (VMS)**: $7.2 million (-50.3% decrease) vs. $14.5 million. - **Other CSCA**: $4.8 million (54.8% increase) vs. $3.1 million. - **Gross Profit**: Gross profit was $754.9 million in 2025, down from $779.1 million in 2024. - **Gross Profit %**: The gross profit percentage increased by 30 basis points to 29.2% in 2025 from 28.9% in 2024. - **Operating Income (Loss)**: CSCA reported an operating loss of -$669.0 million in 2025, a decrease of 347.9% from an operating income of $269.9 million in 2024, primarily due to a $917.1 million goodwill impairment charge. #### Consumer Self-Care International (CSCI) Segment - **Net Sales**: CSCI net sales decreased by $11.9 million, or 0.7%, to $1,667.7 million in 2025 from $1,679.6 million in 2024. - **Net Sales by Product Category (2025 vs. 2024)**: - **Skin Care**: $407.7 million (-0.6% decrease) vs. $410.0 million. - **Upper Respiratory**: $288.2 million (2.1% increase) vs. $282.1 million. - **Pain and Sleep-Aids**: $235.4 million (6.0% increase) vs. $222.2 million. - **Healthy Lifestyle**: $231.5 million (2.5% increase) vs. $225.8 million. - **VMS**: $161.2 million (-7.1% decrease) vs. $173.5 million. - **Women’s Health**: $143.5 million (8.0% increase) vs. $132.8 million. - **Oral Care**: $97.5 million (-2.0% decrease) vs. $99.4 million. - **Digestive Health**: $40.3 million (10.4% increase) vs. $36.5 million. - **Other CSCI**: $62.4 million (-35.8% decrease) vs. $97.3 million. - **Gross Profit**: Gross profit was $739.7 million in 2025, down from $763.5 million in 2024. - **Gross Profit %**: The gross profit percentage decreased by 110 basis points to 44.4% in 2025 from 45.5% in 2024. - **Operating Income (Loss)**: CSCI reported an operating loss of -$228.8 million in 2025, a decrease of 317.9% from an operating income of $105.0 million in 2024, primarily due to a $407.1 million goodwill impairment charge. #### Cash Flow - **Net Cash from Operating Activities**: Net cash from operating activities decreased by $124.4 million to $238.5 million in 2025 from $362.9 million in 2024. - **Net Cash for Investing Activities**: Net cash for investing activities was -$75.4 million in 2025, compared to $78.8 million from investing activities in 2024. - **Net Cash for Financing Activities**: Net cash for financing activities was -$220.5 million in 2025, compared to -$611.0 million in 2024. - **Capital Expenditures**: Capital expenditures totaled $93.4 million in 2025. #### Other Key Financial Metrics - **Unallocated Expenses**: Unallocated expenses decreased by $37.8 million to $224.3 million in 2025 from $262.1 million in 2024. - **Interest Expense, Net**: Interest expense, net decreased by $25.3 million to $162.5 million in 2025 from $187.8 million in 2024. - **Other (Income) Expense, Net**: Other (income) expense, net was $13.2 million in 2025, a decrease of $14.1 million in income compared to -$0.9 million in 2024. - **Loss on Extinguishment of Debt**: There was no loss on extinguishment of debt in 2025, compared to $6.7 million in 2024. - **Effective Tax Rate**: The effective tax rate on the pre-tax loss was -8.0% in 2025, compared to -99.3% in 2024. - **Working Capital**: Working capital increased to $1,043.7 million in 2025 from $915.3 million in 2024. - **Total Indebtedness**: Total indebtedness outstanding was $3.6 billion at December 31, 2025. - **Lease Liabilities**: Total lease liabilities were $190.5 million in 2025, down from $195.1 million in 2024. - **Contractual Obligations**: Total contractual obligations amounted to $5,688.7 million, with $710.3 million due in 2026, $943.0 million in 2027-2028, $1,979.7 million in 2029-2030, and $2,055.7 million after 2030. #### Unique Metrics and Restructuring Programs - **Supply Chain Reinvention Program**: This program achieved approximately $157 million of annualized benefits by the end of 2025, with total costs incurred of approximately $286 million. - **Project Energize**: This program delivered approximately $167 million of annualized pre-tax savings by the end of 2025, with restructuring and related charges of approximately $138 million. - **Goodwill Impairment**: Perrigo Company plc (培瑞克) recognized a total goodwill impairment of $1,325.3 million in 2025, comprising $917.1 million for CSCA and $407.1 million for CSCI. - **Richard Bittner Business Divestiture**: The sale of this business in April 2025 resulted in a pre-tax loss of -$1.6 million and a total impairment charge of $3.1 million, including a $1.2 million goodwill impairment. - **Dermacosmetics Business Divestiture**: As of December 31, 2025, this business was classified as held for sale, with assets of $272.6 million and liabilities of $26.8 million. #### Outlook / Guidance Perrigo Company plc (培瑞克) anticipates 2026 capital expenditures to be between $90 million and $130 million. The company estimates a gross increase to global cost of goods sold of approximately $30 million to $40 million on a full-year basis starting in 2026 due to tariffs. Furthermore, due to a segment reorganization in the first quarter of 2026, structural non-cash goodwill impairment charges are estimated to range up to $350 million. ### 相關股票 - [Perrigo (PRGO.US)](https://longbridge.com/zh-HK/quote/PRGO.US.md) ## 相關資訊與研究 - [01:40 ETVARON Marks Earth Hour 2026 with a Call for Sustainable Respiratory Care and Climate Action](https://longbridge.com/zh-HK/news/281607445.md) - [Cloudbreak Pharma's 2025 Loss Narrows](https://longbridge.com/zh-HK/news/281317115.md) - [Temas Resources Corp. provides updates on FY 2025](https://longbridge.com/zh-HK/news/281523634.md) - [PT Mora Telematika Indonesia Tbk Reports Earnings Results for the Full Year Ended December 31, 2025](https://longbridge.com/zh-HK/news/281402460.md) - [Guan Chao's Loss Balloons in 2025](https://longbridge.com/zh-HK/news/281314987.md)